Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | SI | P14410 | 2/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24199607 | 0.81 | MGAM (0.38) | MGAMGAASIMGAM2CA1 | |
| SCHEMBL24199639 | 0.76 | MGAM (0.32) | MGAMGAASIMGAM2CA1 | |
| SCHEMBL9254498 | 0.76 | GAA (0.36) | MGAMGAASIMGAM2CTDSP1 | |
| SCHEMBL20217097 | 0.75 | MGAM (0.41) | MGAMGAASIMGAM2CA1 | |
| SCHEMBL20217055 | 0.74 | PPM1B (0.35) | MGAMGAASIMGAM2CA1 | |
| SCHEMBL20217024 | 0.74 | PPM1B (0.35) | MGAMGAASIMGAM2CA1 | |
| SCHEMBL20230433 | 0.74 | PPM1B (0.35) | MGAMGAASIMGAM2CA1 | |
| SCHEMBL20230431 | 0.74 | PPM1B (0.35) | MGAMGAASIMGAM2CA1 | |
| SCHEMBL26455239 | 0.74 | GAA (0.33) | GAAKMT2ATSHR | |
| SCHEMBL1841628 | 0.72 | CA2 (0.54) | CA1CA2CTDSP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132377-A9 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2023-04-27 | — | — | US | disclosed |
| US-20230132377-A9 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2023-04-27 | — | — | US | disclosed |
| US-20220017898-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2022-01-20 | — | — | US | disclosed |
| US-11028117-B2 | Bicyclic nucleosides and oligomers prepared therefrom | Universität Bern (CH) | 2021-06-08 | — | — | US | disclosed |
| US-20190345188-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | Universität Bern (CH) | 2019-11-14 | — | — | US | disclosed |
| WO-2018099946-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | Universität Bern (CH) | 2018-06-07 | — | — | WO | disclosed |
| EP-3330276-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | Universität Bern (CH) | 2018-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028117-B2 | Bicyclic nucleosides and oligomers prepared therefrom | RRM2, NUDT1, REV1 | MGAM 1908/4885GAA 2300/4885SI 3096/4885 |
| US-20190345188-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | RRM2, PRPF31, SLC29A2 | MGAM 1335/4885GAA 1698/4885SI 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.